Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis
Results of the randomized investigation by the thoraxcenter of antisense dna using local delivery and ivus after coronary stenting (ITALICS) trial
Michael J. B. Kutryk, MD, PhD*,
David P. Foley, MD, PhD*,
Marcel van den Brand, MD, PhD*,
Jaap N. Hamburger, MD, PhD*,
Willem J. van der Giessen, MD, PhD*,
Pim J. deFeyter, MD, PhD, FACC*,
Nico Bruining, PhD*,
Manel Sabate, MD, PhD* and
Patrick W. Serruys, MD, PhD, FACC*,*
* Department of Interventional Cardiology, Thoraxcenter, University Hospital Dijkzigt, Rotterdam, The Netherlands
View larger version (23K):
[in a new window]
|
Figure 1 Patient flow in the ITALICS trial.
|
|
View larger version (10K):
[in a new window]
|
Figure 2 Boxplot of serum concentrations of LR-3280. Arterial blood samples were drawn from 20 patients immediately (time 0) and at 10 min and 30 min after the intracoronary local administration of LR-3280. Bars represent median values, and boxes represent 25th and 75th percentiles. Extreme (asterisk) and outlying (solid circle) points are shown.
|
|
View larger version (12K):
[in a new window]
|
Figure 3 Kaplan-Meier survival curves for major cardiac events (death, myocardial infarction, coronary artery bypass surgery and repeat percutaneous revascularization of the target lesion). p = 0.91 determined by the log-rank test. The cluster of events just after 180 days reflects the scheduled follow-up. Dashed line = placebo group; solid line = LR-3280 group.
|
|
|
